Group 1: Market Trends and Developments - The brain-computer interface (BCI) sector is transitioning from clinical validation to commercial scalability, with 2026 expected to be a pivotal year for industrialization [2] - China's BCI market is projected to grow from 3.2 billion yuan in 2024 to 5.58 billion yuan in 2027, reflecting a compound annual growth rate of approximately 20% [2] - Global BCI market is anticipated to exceed 40 billion USD by 2030 [2] Group 2: Company Innovations and Collaborations - Yingkang Life has developed a comprehensive management solution for Parkinson's treatment using BCI technology, having completed over 20 deep brain stimulation surgeries [2] - Cheng Yi Tong's recent patent for "brainwave acquisition devices" is expected to enhance its core technology and market share in the BCI field [3] - Entropy Technology plans to launch a prototype BCI product by March 2026, focusing on commercial applications [3] - Yingqu Technology collaborates with various partners to develop BCI-related products, including brainwave monitoring headbands and rehabilitation robots [4] - Hanwei Technology has made breakthroughs in non-invasive flexible BCI materials, although commercial applications remain uncertain [5] - Daoshi Technology has strategically invested in Qiangnao Technology to enhance its capabilities in BCI applications across medical rehabilitation and education [6] - Sanbo Brain Science is advancing its "North Brain No. 2" project, focusing on flexible microelectrode technology for clinical applications [7] - Meihua Medical is a strategic partner in the cochlear implant sector, which is a significant application of BCI technology [7] Group 3: Investment and Strategic Partnerships - Leidi Ke has acquired a 20.41% stake in Aoyi Technology, which specializes in both BCI and robotics, enhancing its capabilities in the medical and health sectors [9] - Lihua Science and Technology's subsidiary, Weiling Medical, is developing a fully implanted wireless BCI system [10] - Guiyan Biotech is exploring precious metal materials for BCI applications, with some products in the experimental stage [11]

在脑机接口、具身智能、商业航天、AI应用等领域逐渐成为战略高地之时，市场的天平正逐渐向硬科 技、有色金属等领域倾斜，传统的大消费正面临销量下滑、行业景气度低迷等多重严峻的挑战。 食品饮料等4个行业持股数连续3个季度下降 从历史数据来看，申万食品饮料行业指数已年线5连阴，2026年开年以来上涨动能依然不足，开年首周 涨幅位居申万31个行业倒数第6。 从行业内单家公司持股情况来看，以持股数量进行统计，北向资金连续3个季度减仓的食品饮料公司有8 家，主要以酒类公司为主，其中贵州茅台的持股数量较2025年一季度末下降超过30%。 实际上，拉长时间发现，贵州茅台遭北向资金减仓已不是新鲜事。截至2025年末，北向资金持有贵州茅 台股份数量5504.88万股，2024年末持股7751.16万股，2023年末持股8631.29万股，2021年末持股8968.18 万股，2019年末及2020年末持股数量均超过1亿股。相比2020年二季度末的持股峰值1.06亿股，北向资 金最新持有贵州茅台的股份数量接近腰斩。 | 持股政量(万股) 持股市值(亿元) 占全部A股(%)(公布) 占流通A股(%)(计算) 占自由流通股比(%) | ...

Core Insights - The report maintains a strong market rating for the medical device industry, emphasizing the importance of capitalizing on overseas expansion and the commercialization of AI in healthcare [1][3][5] Medical Device Strategy - The strategy focuses on a three-step approach: prioritizing overseas expansion, benefiting from centralized procurement, and being sensitive to fiscal policies [3][5] - The report highlights the acceleration of overseas growth, particularly in high-value orthopedic, electrophysiology, and robotic sectors, which are expected to be the main contributors to growth in 2025 [5][24] - Companies such as MicroPort, Tianzhihang, and Weigao are recommended for their potential in overseas markets and innovative product offerings [5][24] AI Applications and Brain-Computer Interfaces - The report identifies a significant opportunity in AI applications, with a focus on the commercialization phase driven by policy support and market demand [4][9] - The brain-computer interface sector is poised for growth, with several leading companies expected to go public soon, which could catalyze the market [9][24] Financial Performance and Market Trends - The medical device sector is showing signs of recovery, with Q3 2025 revenues reaching 593.7 billion yuan, a year-on-year increase of 2.9%, indicating a clear upward trend [13][31] - The report notes a significant contraction in fund allocation to the medical device sector, dropping from 24.5% to 15% from Q3 2022 to Q3 2025, suggesting potential for valuation recovery [14][21] Overseas Growth Potential - The report emphasizes the importance of overseas markets, particularly in Europe and the U.S., where companies are transitioning from product-focused strategies to comprehensive commercialization partnerships [5][24] - Key growth areas include surgical robots and high-value consumables, with companies like Tianzhihang and MicroPort leading the charge in international markets [24][30] Fiscal Policy Impact - The report discusses the sensitivity of equipment demand to fiscal policies, with expectations of a more favorable environment as inventory levels decrease and demand normalizes [31][34] - The anticipated release of more proactive fiscal signals in the upcoming years is expected to support the recovery of the medical device sector [31][34]

Core Viewpoint - The release of the "Guidelines for Evaluation of Brain-like Computing Systems and Training Algorithms" marks a significant step in the standardization of brain-like computing technology in China, with Shenzhen Brain-Machine Starlink Technology Co., Ltd. playing a crucial role in its development alongside top universities and research institutions [1][2]. Group 1: Company Overview - Shenzhen Brain-Machine Starlink Technology Co., Ltd. focuses on artificial intelligence and aims to establish a comprehensive development system from basic research to technology transfer and industrial implementation in the brain-machine interface field [2]. - The company integrates brain-machine interface applications with neural modulation technologies to accelerate the development of diagnostic products for neurological diseases such as Alzheimer's, autism, and depression [2]. Group 2: Industry Context - The brain-machine interface technology is on the verge of explosive growth, with significant potential across various sectors including medical rehabilitation, consumer electronics, education, entertainment, and smart manufacturing [3]. - A market research report predicts that the global brain-machine interface market could exceed hundreds of billions of dollars by 2030, with the medical and health sector being the primary growth area [3]. Group 3: Collaborative Efforts - The collaboration between Shenzhen Brain-Machine Starlink and leading domestic universities and research institutions in standard formulation highlights the company's leading position and strong technical foundation in the brain-like computing field [4]. - The company has announced a partnership with leading immunodiagnostic firm Yihuilong to advance the clinical application and industrialization of brain-machine interface technology in various diagnostic fields [4].

★ 宏观动态 ★ 商务部发布关于中欧电动汽车案磋商进展的通报 据中国商务部网站，为落实中欧领导人会晤共识，妥善解决欧盟对华电动汽车案，中欧双方本着相互尊重的态 度，进行了多轮磋商。双方一致认为，有必要向对欧盟出口纯电动汽车的中国出口商，提供关于价格承诺的通 用指导，以便中国出口商可通过更加实用、有针对性且符合世贸组织规则的方式，解决相关关注。为此，欧方 将发布《关于提交价格承诺申请的指导文件》，并在文件中确认，欧方将秉持非歧视原则，根据世贸组织规则 有关规定，对每一项价格承诺申请，适用相同法律标准，并以客观和公正的方式进行评估。这充分体现了中欧 双方的对话精神和磋商成果。中欧双方有能力、有意愿，在世贸组织规则框架下，通过对话磋商妥善化解分 歧，维护中欧及全球汽车产业链供应链稳定。这不仅有利于中欧经贸关系健康发展，也有利于维护以规则为基 础的国际贸易秩序。 摩根大通：AI需求井喷将推动基建与机器人领域并购浪潮 摩根大通指出，人工智能需求的爆发式增长及海量资本涌入AI产业，正推动电力系统、热管理、机器人及工 业软件领域形成并购热点。据该行预测，全球对数据中心、AI基础设施及相关电力供应的投资规模预计将达5 万亿— ...

Core Viewpoint - The company, Innovation Medical (002173.SZ), has noted increased market attention on its brain-computer interface business, particularly through its subsidiary, Boling Brain Machine (Hangzhou) Technology Co., Ltd. [1] Group 1: Company Overview - Boling Brain Machine was established in early 2021 and is expected to be included in the company's consolidated financial statements by August 2025 [1] - The primary products are designed for rehabilitation training of patients with cerebrovascular diseases, mainly focusing on stroke and hemiplegia [1] Group 2: Product Development and Financial Performance - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" has completed multi-center clinical trials but has not generated revenue in 2025 [1] - The operating losses for Boling Brain Machine were 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]

他对记者解释，在脑机接口系统中，"硬件"如同肉体，由脑虎科技、景昱医疗等公司提供的电极或外设 构成；"灵魂"则是介于大脑与外设之间的算法系统，脑电分析解码是它们专注研究的领域。 作为我国脑机接口技术发展的前沿阵地，上海已形成覆盖侵入式、半侵入式和非侵入式技术的完整研发 体系。未来五年，上海将多层次培育更多脑机接口技术和产品应用落地。 日前公布的《上海市脑机接口未来产业培育行动方案（2025-2030年）》（下称"方案"）提出，2027年 前，实现高质量脑控，半侵入式脑机接口产品在国内率先实现临床应用，侵入式脑机接口研发取得突 破，脑机接口创新生态初步构建。具体围绕加速脑机接口产品化、构建共性技术研发服务平台、推动临 床试验与应用示范、健全产品标准与检测体系、培育产业创新生态等方面展开。 2024年6月以来，上海围绕强化科技创新策源功能，聚焦脑机接口等未来产业新赛道，健全"比选寻优、 动态优化"未来产业培育机制，建立专业化项目经理队伍，实施全生命周期项目管理。 去年12月举行的"2025脑机接口大会"上，多项新技术和产品首发，并揭牌了"脑机接口产业联盟长三角 分联盟"。"上海在脑机接口技术领域取得了系列阶段性突 ...

Group 1 - The core business of the company is divided into three main sectors: military electronics, public safety, and high-end medical equipment [1] - The company has not yet engaged in brain-computer interface related businesses or commercial aerospace activities [1]

Macro and Strategy Research - The US manufacturing PMI has further declined in December 2025, marking the largest month-on-month drop since 2024, indicating a prolonged downturn for 10 months, while the service sector PMI remains strong, highlighting structural divergence in the US economy [2][3] - In China, the manufacturing PMI returned above the threshold in December 2025, with improvements in both supply and demand, while the non-manufacturing sector also showed unexpected recovery [3] Fixed Income Research - In December 2025, the central bank's liquidity net injection exceeded 800 billion, with money market rates remaining low, while the yield on 10Y government bonds rose by 1 basis point to 1.85% by the end of December [7][9] - The bond market is expected to maintain a range-bound pattern, with inflation and monetary policy acting as anchors for the upper and lower bounds of this range [9] Industry Research - The listing of Rebio Biotech on the Hong Kong Stock Exchange has increased attention on the small nucleic acid sector, with significant developments in the industry including the approval of new drugs and strategic partnerships [10][12][13] - The SW pharmaceutical index rose by 6.13% in the week of January 5-8, 2026, with all sub-sectors experiencing gains, indicating a strong market performance [13]

Core Viewpoint - Innovation Medical (002173) has experienced significant stock price fluctuations, with a cumulative increase of over 20% in closing prices over three consecutive trading days, indicating heightened market interest in the company's brain-computer interface business [1] Group 1: Stock Performance - The company's stock price showed abnormal volatility on January 8, 9, and 12, with a cumulative price deviation exceeding 20% [1] - This fluctuation is in accordance with the trading rules of the Shenzhen Stock Exchange, categorizing it as an abnormal trading situation [1] Group 2: Business Overview - The company's subsidiary, Boling Brain Machine (Hangzhou) Technology Co., Ltd., was established in early 2021 and is focused on brain-computer interface products [1] - The primary applications of Boling Brain Machine's products are for rehabilitation training of patients with cerebrovascular diseases, particularly those suffering from stroke-related paralysis [1] - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" has completed multi-center clinical trials but has not yet generated revenue as of 2025 [1] Group 3: Financial Performance - Boling Brain Machine reported operating losses of 6.6017 million yuan in 2023 and 8.6641 million yuan in 2024 [1]